These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

425 related items for PubMed ID: 20589677

  • 1. Colorectal cancer screening comparing no screening, immunochemical and guaiac fecal occult blood tests: a cost-effectiveness analysis.
    van Rossum LG, van Rijn AF, Verbeek AL, van Oijen MG, Laheij RJ, Fockens P, Jansen JB, Adang EM, Dekker E.
    Int J Cancer; 2011 Apr 15; 128(8):1908-17. PubMed ID: 20589677
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Fecal occult blood testing when colonoscopy capacity is limited.
    Wilschut JA, Habbema JD, van Leerdam ME, Hol L, Lansdorp-Vogelaar I, Kuipers EJ, van Ballegooijen M.
    J Natl Cancer Inst; 2011 Dec 07; 103(23):1741-51. PubMed ID: 22076285
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness analysis of the optimal threshold of an automated immunochemical test for colorectal cancer screening: performances of immunochemical colorectal cancer screening.
    Berchi C, Guittet L, Bouvier V, Launoy G.
    Int J Technol Assess Health Care; 2010 Jan 07; 26(1):48-53. PubMed ID: 20059780
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population.
    van Rossum LG, van Rijn AF, Laheij RJ, van Oijen MG, Fockens P, van Krieken HH, Verbeek AL, Jansen JB, Dekker E.
    Gastroenterology; 2008 Jul 07; 135(1):82-90. PubMed ID: 18482589
    [Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness analysis on screening for colorectal neoplasm and management of colorectal cancer in Asia.
    Tsoi KK, Ng SS, Leung MC, Sung JJ.
    Aliment Pharmacol Ther; 2008 Aug 01; 28(3):353-63. PubMed ID: 18638075
    [Abstract] [Full Text] [Related]

  • 12. Immunochemical testing of individuals positive for guaiac faecal occult blood test in a screening programme for colorectal cancer: an observational study.
    Fraser CG, Matthew CM, Mowat NA, Wilson JA, Carey FA, Steele RJ.
    Lancet Oncol; 2006 Feb 01; 7(2):127-31. PubMed ID: 16455476
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening.
    Lansdorp-Vogelaar I, van Ballegooijen M, Zauber AG, Habbema JD, Kuipers EJ.
    J Natl Cancer Inst; 2009 Oct 21; 101(20):1412-22. PubMed ID: 19779203
    [Abstract] [Full Text] [Related]

  • 15. Comparison of guaiac and immunological fecal occult blood tests in colorectal cancer screening: the patient perspective.
    Deutekom M, van Rossum LG, van Rijn AF, Laheij RJ, Fockens P, Bossuyt PM, Dekker E, Jansen JB.
    Scand J Gastroenterol; 2010 Nov 21; 45(11):1345-9. PubMed ID: 20560814
    [Abstract] [Full Text] [Related]

  • 16. Comparison of a guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a general average risk population.
    Guittet L, Bouvier V, Mariotte N, Vallee JP, Arsène D, Boutreux S, Tichet J, Launoy G.
    Gut; 2007 Feb 21; 56(2):210-4. PubMed ID: 16891354
    [Abstract] [Full Text] [Related]

  • 17. Lower risk of advanced neoplasia among patients with a previous negative result from a fecal test for colorectal cancer.
    Denters MJ, Deutekom M, Bossuyt PM, Stroobants AK, Fockens P, Dekker E.
    Gastroenterology; 2012 Mar 21; 142(3):497-504. PubMed ID: 22108194
    [Abstract] [Full Text] [Related]

  • 18. Contribution of the OC Sensor® immunoassay in comparison to the Hemoccult II® guaiac-test in organized colorectal cancer screening.
    Vitellius C, Laly M, Banaszuk AS, Deherce I, Cornet N, Bertrais S, Saulnier P, Caroli-Bosc FX.
    Eur J Epidemiol; 2019 Feb 21; 34(2):163-172. PubMed ID: 30536183
    [Abstract] [Full Text] [Related]

  • 19. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics.
    Allison JE, Sakoda LC, Levin TR, Tucker JP, Tekawa IS, Cuff T, Pauly MP, Shlager L, Palitz AM, Zhao WK, Schwartz JS, Ransohoff DF, Selby JV.
    J Natl Cancer Inst; 2007 Oct 03; 99(19):1462-70. PubMed ID: 17895475
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.